Telmisartan and enalapril in type 2 diabetes: Diabetics Exposed to Telmisartan and Enalapril (DETAIL) study

Sign In to gain access to subscriptions and/or personal tools.

This Article

	Full Text (PDF)
	Alert me when this article is cited
	Alert me if a correction is posted
	Citation Map

Services

	Email this article to a friend
	Similar articles in this journal
	Alert me to new issues of the journal
	Add to Saved Citations
	Download to citation manager
	Request Permissions
	Request Reprints
	Add to My Marked Citations

Citing Articles

	Citing Articles via Google Scholar
	Citing Articles via Scopus

Google Scholar

	Articles by Barnett, A.
	Search for Related Content

Social Bookmarking

	What's this?

Telmisartan and enalapril in type 2 diabetes

Anthony Barnett

Undergraduate Centre, Birmingham Heartlands Hospital, Bordesley Green East, Birmingham, B9 5SS, UK, Anthony.Barnett{at}heartsol.wmids.nhs.uk

Key Words: type 2 diabetes • nephropathy • telmisartan • enalapril • glomerular filtration rate.

References

Barnett AH, Bain SC, Bouter P. et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in Type 2 diabetes and nephropathy. N Engl J Med 2004;351:1952-61.[Abstract/Free Full Text]

Lacourciere Y., Belanger A., Godin C. et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int 2000;58:762-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Pitt B., Poole-Wilson PA, Segal R. et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Dickstein K., Kjekshus J.; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002;360:752-60.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Pfeffer MA McMurray JV, Velzquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both N Engl J Med 2003;349:1893-906 and erratum N Engl J Med 2004;350:203.[CrossRef]

Parving HH, Lehnert H., Brochner-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.[Abstract/Free Full Text]

Brenner BM, Cooper ME, de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.[Abstract/Free Full Text]

Lewis EJ, Hunsicker LG, Clark WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.[Abstract/Free Full Text]

Brown NJ, Vaughan DE Angiotensin-converting enzyme inhibitors. Circulation 1998;97:1411-20.[Abstract/Free Full Text]

Lewis EJ, Hunsicker LG, Bain RP, Rohde RD The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329:1456-62 (and erratum N Engl J Med 1993;330:152).

Ravid M., Savin H., Jutrin I. et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993;118:577-81.[Abstract/Free Full Text]

Rippin J., Bain SC, Barnett AH Rationale and design of Diabetics Exposed to Telmisartan and Enalapril (DETAIL) study. J Diabetes Complications 2002;16:195-200.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Lacourciere Y. Telmisartan Cough Study Group. The incidence of cough: a comparison of lisinopril, placebo and telmisartan, a novel angiotensin II antagonist. Int J Clin Pract 1999;53:99-103.[Web of Science][Medline] [Order article via Infotrieve]